172 results about "Cell marker" patented technology

The present invention provides humanized, chimeric and human anti-CD20 antibodies and CD 20 antibody fusion proteins that bind to a human B cell marker, referred to as CD20, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies and autoimmune diseases, and methods of treatment and diagnosis.

Transcriptomes of individual neurons provide rich information about cell types and dynamic states. However, it is difficult to capture rare dynamic processes, such as adult neurogenesis, because isolation from dense adult tissue is challenging, and markers for each phase are limited. Here, Applicants developed Nuc-seq, Div-Seq, and Dronc-Seq. Div-seq combines Nuc-Seq, a scalable single nucleus RNA-Seq method, with EdU-mediated labeling of proliferating cells. Nuc-Seq can sensitively identify closely related cell types within the adult hippocampus. Div-Seq can track transcriptional dynamics of newborn neurons in an adult neurogenic region in the hippocampus. Dronc-Seq uses a microfluidic device to co-encapsulate individual nuclei in reverse emulsion aqueous droplets in an oil medium together with one uniquely barcoded mRNA-capture bead. Finally, Applicants found rare adult newborn GABAergic neurons in the spinal cord, a non-canonical neurogenic region. Taken together, Nuc-Seq, Div-Seq and Dronc-Seq allow for unbiased analysis of any complex tissue.

A conjugate of a toxin and a cytokine, and a fusion protein comprising a bispecific antibody that has a first specificity for a cell marker specific to a malignant cell and a second specificity for a region of IL-15α, each optionally further comprising a radionuclide, are useful therapeutic reagents for treating leukemias and lymphomas.

The present invention inter alia pertains to therapeutic methods which are based on the use of an agent specifically binding a tumor-associated carbohydrate antigen for the treatment of cancer stem cells and related diseases. Also provided are diagnostic and prognostic methods using a tumor-associated carbohydrate antigen as marker for cancer stem cells.

The present study demonstrates that brimonidine tartrate, an alpha-2 adrenergic receptor agonist, can prevent photoreceptor cell degeneration and the associated Muller cell degenerative signs in an in vitro model of retinal degeneration and retinal detachment (separation of the neuroretina from the retinal pigment epithelium). Similar to control conditions, brimonidine allowed for the formation of highly structured photoreceptor outer segments, prevented the expression of stress markers in Müller cells and preserved the expression patterns of Muller cell markers of proper cell-cell contact and differentiation. Ultrastructural studies also indicated that brimonidine favored the formation of cell-cell junctions between photoreceptor cells and Müller cells, indicating that this phenomenon is associated with the exertion of the neuroprotective effect. The results suggest that brimonidine compounds may be utilized as an effective therapeutic agent for early and late onset retinal degenerations caused by defects in photoreceptor cells, Müller cells or both, and as an adjuvant to therapeutic success in retinal detachment surgery or macular translocation surgery for age-related macular degeneration.

The present invention relates to non-lethal methods of conditioning a recipient for bone marrow transplantation. In particular, it relates to the use of nonlethal doses of total body irradiation, total lymphoid irradiation, cell type-specific or cell marker-specific antibodies, especially antibodies directed to bone marrow stromal cell markers, NK cells, or the CD8 cell marker, cytotoxic drugs, or a combination thereof. The methods of the invention have a wide range of applications, including, but not limited to, the conditioning of an individual for hematopoietic reconstitution by bone marrow transplantation for the treatment of hematologic malignancies, hematologic disorders, autoimmunity, infectious diseases such as acquired immunodeficiency syndrome, and the engraftment of bone marrow cells to induce tolerance for solid organ, tissue and cellular transplantation.

The invention belongs to advanced nanometer material and nanotechnology field, in particular to a super paramagnetism inorganic nanometer microballoon and a preparation method thereof. The super paramagnetism inorganic nanometer microballoon has grain diameters of 80-410nm and hydrophilic surfaces, wherein the magnetism inorganic nanometer microballoon is formed by nano particles with grain diameters of 6-10nm; the nano particles are one or more than one of Fe3O4, Gamma-Fe2O3, MnFe2O4, NiFe2O4 and CuFe2O4; and the surface of the magnetism nanometer microballoon is coated by organic hydrophilicmicromolecule which is one or more than one of oxalic acid, citric acid, dihydroxysuccinic acid, and malic acid. The microballoon has bigger grain diameter and strong external field responsibility, and simultaneously keeps the super paramagnetism character; as the microballon has hydrophilic surface, the microballon can well disperse in water solution. Cell experiments show that the microballon has very low cytotoxicity and is particularly suitable for use in biomedicine, such as cell marks, separation and magnetic resonance imaging, etc.

Hematopoeitic stem / progenitor cells (HSPC) and / or non-T effector cells are genetically modified to express (i) an extracellular component including a ligand binding domain that binds a cellular marker preferentially expressed on an unwanted cell; and (ii) an intracellular component comprising an effector domain. Among other uses, the modified cells can be administered to patients to target unwanted cancer cells without the need for immunological matching before administration.

The invention provides a micro-fluidic chip device for circulating tumor cell (CTC) detection. According to the device, through an integrated micro-fluidic chip mode, functions of blood sample pretreatment, red blood cell lysis, leukocyte screening, circulating tumor cell enrichment, cell marker staining, cleaning and detection, CTC collection and the like are realized. Various functional units ofthe micro-fluidic chip are corresponding to the chip structure. Each solution tanks are connected through microfluidic channels, diameter of the channel matches the structure of researched cells, andfunctional transport of a cell solution in the channel is guaranteed. The device of the invention is used for screening, detecting and collecting circulating tumor cells in peripheral blood sample solutions of patients, providing clinic treatment and guidance and conducting quantitative statistics of circulating tumor cells, and also can be used for downstream single-cell genome and transcriptomeanalysis. The device of the invention is simple to operate, has advantages of saving time cost, realizing automatic detection and raising detection efficiency and analysis efficiency, and has vitallyimportant clinical examination value.

The present invention relates to compositions and methods for treating, characterizing, and diagnosing cancer. In particular, the present invention provides a novel stem cell cancer marker, ALDH1, useful for the diagnosis, characterization, and treatment of solid tumor stem cells.

The invention relates to a silica-coated fluorescent magnetic nanoparticle modified by amino or ester dendrimer. A superparamagetism Fe3O4 inner core is prepared by using a coprecipitation method; Fe3O4 encapsulated by silicon dioxide (Fe3O4 and SiO2) is formed by alkaline hydrolyzation of tetraethoxysilane (TEOS); and a fluorescent dye (fluorescein isothiocyanate FITC) is encapsulated in the silicon dioxide layer in a covalent way so as to facilitate tracing a carrier or to be taken as a model medicament. The carrier can be used for fluorescent tracing; and the external surface of the carrier is coated with polyamide-amine (PAMAM) dendrimer, so that the carrier has a great amount of functional groups used for modifying and used for connecting antibodies easier to target a blood brain barrier, and has the potential of becoming a targeted medicament carrier. Research results show that the two materials are injected through arteria carotis communis and can pass through the blood brain barrier. The ester silica-coated fluorescent magnetic nanoparticle is easier to pass through the blood brain barrier than the amino silica-coated fluorescent magnetic nanoparticle. In addition, the carrier can also be used for marking cells.

The present invention relates to non-lethal methods of conditioning a recipient for bone marrow transplantation. In particular, it relates to the use of nonlethal doses of total body irradiation, total lymphoid irradiation, cell type-specific or cell marker-specific antibodies, especially antibodies directed to bone marrow stromal cell markers or the CD8 cell marker, cytotoxic drugs, or a combination thereof. The methods of the invention have a wide range of applications, including, but not limited to, the conditioning of an individual for hematopoietic reconstitution by bone marrow transplantation for the treatment of hematologic malignancies, hematologic disorders, autoimmunity, infectious diseases such as acquired immunodeficiency syndrome, and the engraftment of bone marrow cells to induce tolerance for solid organ, tissue and cellular transplantation.

The invention discloses a method for annotating cell identities based on single cell transcriptome clustering results. The method comprises the following steps: S1, providing survival cells, establishing a library by using 10X genetics, and sequencing to obtain transcriptome sequencing data; S2, filtering the sequencing data obtained in the step S1, then carrying out initial analysis by using thesoftware cellranger, and outputting original data; S3, analyzing the original data output in the step S2; S4, performing cell identity annotation, including the steps: S41, classifying the tag genes of the Cell Marker database according to cell types; S42, sorting the tag genes screened out by the FindAllMarkers function according to a P value; S43, taking an intersection of the tag gene of each type of cells in the Cell Marker database and a cell subset tag gene screened by the FindAllMarkers function, and scoring according to the intersection gene; and S44, sorting according to the score ofthe gene intersection, and annotating the cell type corresponding to the highest score as the cell identity of the current subgroup. By adopting the method for annotating cell identities based on single cell transcriptome clustering results disclosed by the invention, the cells can be accurately and quickly classified and subjected to identity annotation.

The invention relates to a preparation method of a curie point controllable water-soluble nano ferrite, which comprises the steps of allowing an MnCl2.4H2O solution, a ZnCl2 solution, an FeCl3.6H2O solution and a sodium hydroxide solution to perform precipitation reaction, ultrasonically dispersing a precipitate in an alcohol solution, allowing the precipitate to react with ethyl orthosilicate, and then with 3-amino propyltriethoxysilane after reaction, obtaining a precipitate, dispersing in a PBS (Phosphate Buffer Solution) and obtaining a final product. With the adoption of the technology, the superparamagnetic ferrite which is fine in particle, has controllable curie temperature and good water solubility, can be dissolved in PBS and is bonded with an amino group is prepared, and a foundation can be laid for the ferrite to be inoculated with a tumor antibody and a cell marker to have a target positioning effect.

The invention provides a positioning method and a positioning device. The positioning device applied to a base station side comprises the following steps: acquiring the positioning measurement information of a terminal; receiving a positioning measurement request triggered by a preset positioning entity, wherein the positioning measurement request contains an indication for positioning and measuring the terminal by virtue of a coverage enhancement grade; and sending positioning measurement information of the terminal to the preset positioning entity according to the positioning measurement request so as to drive the preset positioning entity to position the terminal according to the positioning measurement information. According to the embodiment of the invention, the terminal is roughly positioned by a network side through the coverage enhancement grade and a service cell marker of the terminal, so that the extra expenditure of the terminal caused by the positioning of the terminal in the coverage enhancement grade range is avoided, the complexity of the terminal is reduced, and the power consumption of the terminal is saved; or the terminal is subjected to positioning measurement by the network side through a repeated sending property of the coverage enhancement grade, so that a relatively accurate positioning measurement result is obtained, and the positioning measurement precision is improved.

The present invention provides polynucleotides and polypeptides (VECSM polynucleotides and polypeptides) that are differentially expressed in vascular endothelial cells. The invention further provides a variety of compositions, diagnostic, and therapeutic methods based on identification of these markers. In particular, the invention provides a targeting agent linked to a functional moiety, wherein the functional moiety can comprise any of a number of different agents, including imaging agents, cytotoxic agents, and stimulators or inhibitors of angiogenesis.

An objective of the present invention is to provide: a cancer stem cell isolated using a cell marker; a substantively homogeneous cancer stem cell population including said cancer stem cell; and a method of preparing said cancer stem cell population. Another objective of the present invention is to provide: a method for separating cancer stem cells with a high proliferative potential and those with a low proliferative potential; a method for inducing cancer stem cells to have a different proliferative potential; and cancer stem cells separated or induced by these separation or induction methods. A further objective of the present invention is to provide: a method of screening for pharmaceuticals using said cancer stem cell or cancer stem cell population; a method for detecting the presence of said cancer stem cell or cancer stem cell population and for identifying or quantifying the same. The present inventors discovered that highly pure colon cancer stem cells (CSC) can be obtained in a large quantity, and identified two types of states of colon CSCs distinguishable through Lgr5 expression.

The invention provides a cell subset annotation method based on single cell transcriptome sequencing. The cell subset annotation method comprises the following steps: 1) 10x barcode UMI identification; 2) genome comparison; 3) gene expression profile comparison; 4) low-quality cell filtering and data homogenization; 5) cell population clustering; 6) marker gene extraction; 7) cell subset annotation. The invention belongs to the technical field of biological information analysis, and provides a cell subset annotation method based on single-cell transcriptome sequencing, which solves the problem of single-cell subset annotation, so that single-cell sequencing data can support cell annotation according to a gene expression profile and / or a cell Marker gene after conventional analysis. Therefore, organic combination of different annotation methods is realized, and the distribution condition and related information of cell types are obtained.

Purified preparations of human embryonic stem cells with certain population-specific characteristics are disclosed. This preparation is characterized by the positive expression of the following pluripotent cell surface markers: SSEA-1 (−); SSEA-4 (+); TRA-1-60 (+); TRA-1-81 (+); alkaline phosphatase (+), as well as a set of ES cell markers including Oct-4, Nanog, Rex1, Sox2, Thy1, FGF4, ABCG2, Dppa5, UTF1, Cripto1, hTERT, Connexin-43 and Connexin-45. The cells of the preparation are negative for lineage specific markers like Keratin 8, Sox-1, NFH (ectoderm), MyoD, brachyury, cardiac-actin (mesoderm), HNF-3 beta, albumin, and PDX1 (endoderm). The cells of the preparation are human embryonic stem cells, have normal karyotypes, exhibit high telomerase activity and continue to proliferate in an undifferentiated state after continuous culture for over 40 passages. The embryonic stem cell line Relicell™ hES1 also retains the ability, throughout the culture, to differentiate into cell and tissue types derived from all three embryonic germ layers (endoderm, mesoderm and ectoderm). Methods for isolating a human embryonic stem cell line are also disclosed.

The present invention provides a preparation method of fluorescent carbon nanoparticles by direct hydrothermal carbonization of kelp. The method includes the steps of: (1) washing fresh kelp with water, segmenting, drying, grinding into powder by a pulverizer, screening the powder to obtain a kelp powder; (2) weighing a certain amount of kelp powder, dispersing in alcohol liquid, fully stirring to obtain a paste, transferring the paste into a high-pressure reactor, and conducting high temperature reaction for some time to obtain a dark brown product; (3) dissolving the product with deionized water, conducting vacuum filtration, conducting rotary evaporation on a filtrate, centrifuging the concentrated solution, removing a supernatant, placing the precipitate in an oven for drying to obtain carbon nano particle powder; and dispersing a certain amount of powder in deionized water to obtain the fluorescent carbon nanoparticles dispersion. The method of the invention has simple operation; the prepared product has good biocompatibility, excellent fluorescent performance, and shows application prospects in the fields of sensors, light emitting devices, cell marking and biological imaging.

The invention discloses a sub-totipotent stem cell from cut human umbilical cord or placenta, wherein the cell marker is CD151<+>OCT4<+>CD184<->; the cell grows adhering to the wall in a culture container and can differentiate to the body entoderm, mesoblast and ectoderm tissues. The invention also discloses a preparation method of the sub-totipotent stem cell and an application thereof for preparing drug for treating cell injuries or cell aging diseases, and an application thereof as a carrier cell of a gene treatment drug.

The invention relates to a method and apparatus for updating a notification area, and belongs to the technical field of wireless communication. The method includes the following steps: in a non-active state, based on a stored cell marker list, determining a first cell marker for currently updating a notification area, wherein the cell marker list stores a plurality of cell markers and the current signal intensity of the cell corresponding to each cell; transmitting a first notification region updating request to a base station, wherein the first notification region updating request carries a first cell marker and a base station marker of the base station which is connected to when the notification region updating is conducted previously; and receiving an allowance updating notice transmitted by the base station, updating the notification region as the cell corresponding to the first cell marker. According to the invention, when the UE is in a non-active state, the notification region is updated as the cell corresponding to the first cell marker, and the method herein can update the notification region if the notification region changes.

A data classification supporting method capable of easily discriminating a cell to which unknown data belongs and cells similar to the unknown data from each other is obtained. This classification compares cell vector data of each cell with the unknown data, decides a cell having cell vector data closest to the unknown data and cells having cell vector data secondly to nthly close to the unknown data as a minimum cell and similar cells respectively and displays a minimum cell mark and similar cell marks indicating the minimum cell and the similar cells respectively on a classification map.

The invention discloses new application of axitinib. Axitinib can be used for preparing medicine for promoting white fat cell browning and used for preventing and treating obesity and diseases related to obesity. The medicine can promote primary white fat cell browning in vitro, thereby enhancing expression of brown fat cell marker gene uncoupling protein 1 (UCP1), and can promote the increase of beige fat cells in white fat tissue of groin and the increase of expression of UCP1; the medicine can resist obesity and insulin insensitivity caused by high-fat diet and has an effect on treating fatty livers.

The purpose of the present invention is to provide a method of purification and preparation of cultured corneal endothelial cells, and in particular, to provide cell surface markers for use in corneal endothelial cells not including transformed cells. Provided are cell markers for distinguishing normal cells and transformed cells, in particular normal and transformed corneal endothelium cells. These cell markers relate to specific cell surface markers, for example, to a normal corneal endothelial surface marker such as CD166, and a transformed cell surface marker such as CD73. By using the transformed cell surface marker such as CD73 to remove transformed cells by sorting, it becomes possible to improve purity of a normal cultured corneal endothelium. By using normal corneal endothelial surface marker such as CD166, or by combined use with the transformed cell surface marker, it becomes possible to provide a means for verifying the purity of a prepared corneal endothelium.

The present invention discloses a method for simultaneous detection of cancer-associated fibroblasts and expressed proteins thereof, belonging to the technical field of tissue immunofluorescence. According to the method, a first type of quantum dot is used for labeling the antibody of a cell marker of the cancer-associated fibroblasts, or labeling a secondary antibody capable of specific binding to the antibody of the cell marker of the cancer-associated fibroblasts, or labeling streptavidin, and at least a second type of quantum dot is used for labeling the antibody of an expressed protein of the cancer-associated fibroblasts, or labeling a secondary antibody capable of specific binding to the antibody of the expressed protein of the cancer-associated fibroblasts, or labelling streptavidin; wherein the emission wavelengths of the first type of quantum dot and the second type of quantum dot are different from each other, and the first type of quantum dot and the second type of quantum dot does not label the streptavidin simultaneously. The invention also discloses a kit for simultaneous detection of cancer-associated fibroblasts and expressed protein thereof. The method of the invention is simple, efficient, accurate, and simultaneous in detection, suitable for promotion to the simultaneous labeling and quantitative analysis of a variety of other cancer-associated markers.

A method of identifying an antigen-specific regulatory T cell (Treg) from a subject is discussed wherein the method comprises quantitatively or qualitatively detecting co-expression of each of cell markers CD4, CD25 and CD134, or alternatively, N each of cell markers CD8, CD25 and CD137, as well as one or more cell markers selected from the group of Treg cell markers consisting of CD39, CD73, CD127, CTLA-4 and Foxp3 on a cell in a suitable lymphocyte-containing sample from the subject in response to exposure to a target antigen. Also discussed are methods of isolating and expanding the identified antigen-specific Treg population, which may permit antigen-specific Treg cell therapy.

Isolated, mammalian, bone marrow-derived, lineage negative hematopoietic stem cell populations (Lin− HSC) contain endothelial progenitor cells (EPC) capable of forming retinal blood vessels. At least about 50% of the cells in the isolated Lin− HSC population include cell surface markers for CD31 and c-kit. Up to about 8% of the cells can include the Sca-1 cell marker, and up to about 4% of the cells can include the Flk-1 / KDR marker. The isolated Lin− HSC populations of the present invention are useful for treatment of ocular vascular diseases. The isolated Lin− HSC populations that have been transfected with therapeutically useful genes are also provided, which are useful for delivering genes to the eye for cell-based gene therapy.

Therapeutic and drug delivery systems are provided in the form of medical devices with coatings for capturing and immobilizing target cells such as circulating progenitor or genetically-altered mammalian cells in vivo. The genetically-altered cells are transfected with genetic material for expressing a marker gene and a therapeutic gene in a constitutively or controlled manner. The marker gene is a cell membrane antigen not found in circulating cells in the blood stream and therapeutic gene encodes a peptide for the treatment of disease, such as, vascular disease and cancer. The coating on the medical device may be a biocompatible matrix comprising at least one type of ligand, such as antibodies, antibody fragments, other peptides and small molecules, which recognize and bind the target cells. The therapeutic and / or drug delivery systems may be provided with a signal source such as activator molecules for stimulating the modified cells to express and secrete the desired marker and therapeutic gene products.

Disclosed is an isolated bone marrow stem cell (BMSC) having undetectable or low levels of selected cell markers including those typical of endothelial, neuronal and smooth muscle cells. Also disclosed are grafts and pharmaceutical products that include such cells. Methods of making the BMSCs are also provided. The invention has a wide spectrum of useful applications including use in the prevention and treatment of cardiovascular disease.